BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

...recombinant form of human ɑ galactosidase A.The agency also granted Priority Review to a BLA for evinacumab...
BioCentury | Jun 20, 2020
Product Development

Regeneron’s commercial future

...U.S. patients. Source: PubMed Among its 11 wholly owned clinical candidates, four target ultra-Orphan diseases: evinacumab...
BioCentury | Jun 11, 2020
Finance

Insiders lead, crossovers join in gene editing play Verve’s $63M round

...Inc. (NASDAQ:ALNY) and Novartis AG (NYSE:NVS; SIX:NOVN) that is under FDA and EMA review; Regeneron’s evinacumab...
BioCentury | Oct 7, 2019
Company News

Amid management shakeup, Akcea strikes latest antisense deal

...Waylivra volanesorsen in the EU. Pfizer and Akcea are trailing one other therapy against ANGPTL3, evinacumab...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

...some LDL receptor function on a combination of evinacumab plus Repatha, alongside other lipid-lowering therapies. Evinacumab...
...at Imperial College London, agreed with Brinton that evinacumab has “considerable potential in homozygous FH.” Evinacumab’s...
...Microsomal triglyceride transfer protein (MTP) PCSK9 - Proprotein convertase subtilisin/kexin type 9 Stephen Hansen, Associate Editor evinacumab (REGN1500) Regeneron...
BioCentury | Aug 14, 2019
Clinical News

Regeneron data could set up first-in-class approval in lipid-lowering indication

...Regeneron's evinacumab could give certain hypercholesterolemia patients a new treatment option, with an FDA submission looming...
...nominal p=0.0203). ELIPSE HoFH's patients were already taking an assortment of lipid-lowering therapies. In the evinacumab...
...Targets: ANGPTL3 - Angiopoietin-like 3; PCSK9 - Proprotein convertase subtilisin/kexin type 9 Paul Bonanos, Associate Editor evinacumab (REGN1500) Regeneron...
BioCentury | Jul 14, 2017
Clinical News

Regeneron reports Phase II data for evinacumab in HoFH

...international Phase II trial in 9 patients with homozygous familial hypercholesterolemia (HoFH) showing that evinacumab (REGN1500...
...4, the primary endpoint, by 49%. Four patients achieved an LDL-C of <100 mg/dL. Additionally, evinacumab...
...designation from FDA to treat HoFH. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Product: Evinacumab ( REGN1500...
BioCentury | May 12, 2017
Clinical News

FDA grants Regeneron's evinacumab breakthrough therapy designation for HoFH

...Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA granted breakthrough therapy designation to evinacumab (REGN1500) to treat homozygous...
...testing for the indication. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Product: Evinacumab (REGN1500) Business: Endocrine/Metabolic Alex Himes evinacumab REGN1500 Regeneron...
BioCentury | Jan 26, 2017
Strategy

Deep roots

...Zetia ezetimibe to treat hypercholesterolemia, hyperlipidemia and cardiovascular diseases, and Regeneron has the anti-ANGPTL3 mAb evinacumab...
BioCentury | Jun 15, 2015
Regulation

LDL in context

...ACL) inhibitor Hypercholesterolemia Ph II (start Ph III by YE15) Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Evinacumab (REGN1500...
Items per page:
1 - 10 of 11